EU uni­ver­si­ties are mis­er­ably lax at re­port­ing clin­i­cal tri­al re­sults, analy­sis sug­gests

The val­ue of pub­lish­ing clin­i­cal tri­al da­ta can­not be ex­ag­ger­at­ed — it is cru­cial to the pace and di­rec­tion of sci­en­tif­ic progress, and crit­i­cal to the knowl­edge base em­ployed by pa­tients, doc­tors and pol­i­cy­mak­ers to make de­ci­sions about the safe­ty, ben­e­fits and adop­tion of treat­ment in­ter­ven­tions. But not every­body is quite as con­cerned with the toll clin­i­cal tri­al trans­paren­cy trans­gres­sions can take on pa­tient health, pub­lic health pol­i­cy and med­ical ad­vance­ment — a new re­port sug­gests Eu­ro­pean Uni­ver­si­ties are ex­tra­or­di­nar­i­ly guilty of these re­port­ing vi­o­la­tions.

The re­port, pub­lished on Tues­day, eval­u­at­ed the per­for­mance of 30 Eu­ro­pean uni­ver­si­ties that have spon­sored the largest num­ber of clin­i­cal tri­als gov­erned by the Eu­ro­pean Union. Since 2014, the EU has man­dat­ed every study reg­is­tered on the EU clin­i­cal tri­als reg­istry post sum­ma­ry re­sults on­to the reg­istry with­in one year of com­ple­tion (6 months for pe­di­atric tri­als) — these rules al­so ap­ply to tri­als com­plet­ed pri­or to 2014, and must be ad­hered to ir­re­spec­tive of whether re­sults have been pub­lished in aca­d­e­m­ic jour­nals.

Al­to­geth­er the eval­u­at­ed uni­ver­si­ties have spon­sored 4,575 clin­i­cal tri­als, of which re­sults are ver­i­fi­ably due for 940 tri­als. But on­ly the re­sults of 162 (17%) tri­als have been post­ed on the EU Clin­i­cal Tri­als Reg­is­ter, the re­port found. Da­ta for the study was col­lat­ed and analysed by a con­sor­tium of Eu­ro­pean in­sti­tu­tions: UK’s TranspariMED, Ger­many’s BUKO Phar­ma-Kam­pagne, Bel­gium’s Test Aankoop and Nether­land’s Health Ac­tion In­ter­na­tion­al (HAI).

“Fail­ure to ful­ly and rapid­ly re­port clin­i­cal tri­al re­sults is not a vic­tim­less crime…Some (UK) uni­ver­si­ties have al­ready post­ed over 90% of their tri­al re­sults, show­ing that where there is a will, there is a way. Why are uni­ver­si­ties that break the rules still re­ceiv­ing pub­lic funds to run ad­di­tion­al tri­als?” Till Bruck­n­er, founder of TranspariMED said in a state­ment. Truck­n­er co-au­thored a re­port in 2017 that analysed six drug case stud­ies — in­clud­ing Vioxx and Tam­i­flu — in which tri­al opac­i­ty di­rect­ly harmed pa­tients, tax­pay­ers and/or in­vestors.

In the cur­rent analy­sis, most of the 778 clin­i­cal tri­als ver­i­fi­ably miss­ing re­sults were run by uni­ver­si­ties in Den­mark (246 tri­als), Aus­tria (225), and Ger­many (117) and none of the as­sessed uni­ver­si­ties in France, Italy, Nor­way and Swe­den have made a sin­gle clin­i­cal tri­al re­sult pub­lic on the reg­istry, the re­port found.

Da­ta ex­tract­ed from the EU Clin­i­cal Tri­als Reg­is­ter via the EU Tri­als Track­er. Ac­cu­rate as of 01 April 2019.

Click on the im­age to see the full-sized ver­sion

These num­bers above may not even re­flect the ac­tu­al state of af­fairs, giv­en that many tri­als list­ed as “on­go­ing” on the Eu­ro­pean tri­al reg­istry were in fact com­plet­ed long ago, re­searchers un­der­scored. As it stands, EU uni­ver­si­ties are em­pow­ered to up­load their sum­ma­ry re­sults on­to the EU reg­istry as tri­al spon­sors, but they can­not di­rect­ly up­date the sta­tus (on­go­ing/com­plet­ed) of the tri­als. In­stead, uni­ver­si­ties are sup­posed to no­ti­fy their na­tion­al med­i­cines reg­u­la­tor when a tri­al is com­plet­ed, and the reg­u­la­tor is then meant to re­vise the tri­al’s sta­tus on the reg­istry. “For ex­am­ple, uni­ver­si­ties in the Nether­lands have run 967 tri­als in to­tal, but on­ly 23 of those (2.4%) are marked as “com­plet­ed”. This num­ber is com­plete­ly im­plau­si­ble, as reg­istry records show that many of those tri­als start­ed over five years ago. (In the UK, where a reg­istry up­date is on­go­ing, the pro­por­tion of “com­plet­ed” tri­als in the co­hort is 27.4%.),” the re­port not­ed.

A po­ten­tial rea­son why EU re­searchers  — who are not fac­ing the same lev­el of scruti­ny as their UK coun­ter­parts — have not both­ered with com­ply­ing with their trans­paren­cy oblig­a­tions could be the lack of in­cen­tive, Test Aankoop’s Van Hecke Mar­tine told End­points News. “The fo­cus of re­searchers is pub­li­ca­tion of their study re­sults in sci­en­tif­ic jour­nals, as this is re­ward­ed in their pro­fes­sion­al eval­u­a­tion and so it’s im­por­tant for their ca­reer.”

The on­ly bright spark in the re­port were UK uni­ver­si­ties — some of which have re­port­ing rates of over 90%, large­ly due to en­dur­ing pres­sure from par­lia­ment, the pub­lic and re­search fund­ing bod­ies. Out­side of the UK, 730 out of 785 ver­i­fi­ably due tri­als (93%) are cur­rent­ly miss­ing re­sults, da­ta in­di­cat­ed.

“There is no good rea­son why, if UK uni­ver­si­ties can do it, their coun­ter­parts across Eu­rope can’t. This should be the stim­u­lus oth­ers need to get their act to­geth­er and meet their trans­paren­cy oblig­a­tions. The ap­par­ent con­tempt shown by many Uni­ver­si­ties must not be al­lowed to stand.” HAI se­nior pol­i­cy ad­vi­sor An­cel.la San­tos told End­points News.

Once up­on a time, UK uni­ver­si­ties were sim­i­lar­ly lax about their re­port­ing oblig­a­tions. But con­cert­ed pres­sure has yield­ed im­pres­sive re­turns. For ex­am­ple, King’s Col­lege Lon­don en­hanced its re­port­ing rate from a woe­ful 18% to a re­spectable 93% with­in six months. The Uni­ver­si­ty of Not­ting­ham — spot­light­ed by the UK par­lia­ment’s sci­ence and tech­nol­o­gy com­mit­tee for its weak per­for­mance last year — has now post­ed the sum­ma­ry re­sults of over 95% of its tri­als, the re­port not­ed.

But da­ta com­piled by Ben Goldacre, best-sell­ing au­thor, med­ical doc­tor and re­searcher who fo­cus­es on un­pack­ing the mis­use of sci­ence and sta­tis­tics in his books Bad Sci­ence and Bad Phar­ma, out of his lab at the Uni­ver­si­ty of Ox­ford sug­gests that UK uni­ver­si­ties are less re­li­able than drug de­vel­op­ers at ful­fill­ing their clin­i­cal tri­al re­port­ing oblig­a­tions.

Across the At­lantic things aren’t much bet­ter. An analy­sis pub­lished last month by Uni­ver­si­ties Al­lied for Es­sen­tial Med­i­cines (UAEM) and non-prof­it re­search ad­vo­ca­cy group TranspariMED showed that 40 lead­ing US uni­ver­si­ties should have post­ed the re­sults of 450 clin­i­cal tri­als — but over a third (31%) of those re­sults are miss­ing.

Im­age: Shut­ter­stock

Mer­ck is tak­ing the ax to its US op­er­a­tions, cut­ting 500 jobs in its lat­est re­or­ga­ni­za­tion

Merck is cutting 500 jobs in its US sales and headquarters commercial teams in its latest effort to find new ways to streamline the operation.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Alice Shaw, Lung Cancer Foundation of America

Top ALK ex­pert and can­cer drug re­searcher Al­ice Shaw bids adieu to acad­e­mia, hel­lo to No­var­tis

Jay Bradner has recruited a marquee oncology drug researcher into the ranks of the Novartis Institutes for BioMedical Research. Alice Shaw is jumping from prestigious posts intertwined through Mass General, Harvard and Dana-Farber to take the lead of NIBR’s translational clinical oncology group.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Mi­rati preps its first look at their KRAS G12C con­tender, and they have to clear a high bar for suc­cess

If you’re a big KRAS G12C fan, mark your calendars for October 28 at 4:20 pm EDT.

That’s when Mirati $MRTX will unveil its first peek at the early clinical data available on MRTX849 in presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Mirati has been experiencing the full effect of a rival’s initial success at targeting the G12C pocket found on KRAS, offering the biotech some support on the concept they’re after — and biotech fans a race to the top. Amgen made a big splash with its first positive snapshot on lung cancer, but deflated sky-high expectations as it proved harder to find similar benefits in other types of cancers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

The FDA will hus­tle up an ex­pe­dit­ed re­view for As­traZeneca’s next shot at a block­buster can­cer drug fran­chise

AstraZeneca paid a hefty price to partner with Daiichi Sankyo on their experimental antibody drug conjugate for HER2 positive breast cancer. And they’ve been rewarded with a fast ride through the FDA, with a straight shot at creating another blockbuster oncology franchise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Sean Parker, AP

Sean Park­er helps cre­ate a CRISPRed cell ther­a­py 2.0 play — and he’s got a high-pro­file set of lead­ers on the team

You can rack up one more high-profile debut effort in the wave of activity forming around cell therapy 2.0. It’s another appealing Bay Area group that’s attracted some of the top hands in the business to a multi-year effort to create a breakthrough. And they have $85 million in hand to make that first big step to the clinic.

Today it’s Ken Drazan and the team at South San Francisco-based ArsenalBio that are coming from behind the curtain for a public bow, backed by billionaire Sean Parker and a collection of investors that includes Beth Seidenberg’s new venture investment operation based in LA.
Drazan — a J&J Innovation vet with a long record of entrepreneurial endeavors — exited the stage in 2018 when his last mission ended as he stepped aside as president of Grail. It wasn’t long, though, before he was helping out with a business plan for ArsenalBio that revolved around the work of a large group of interconnected scientists supported by the Parker Institute for Cancer Immunology.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Med­ical an­i­ma­tion: Mak­ing it eas­i­er for the site and the pa­tient to un­der­stand

Medical animation has in recent years become an increasingly important tool for conveying niche information to a varied audience, particularly to those audiences without expertise in the specialist area. Science programmes today, for example, have moved from the piece-to-camera of the university professor explaining how a complex disease mechanism works, to actually showing the viewer first-hand what it might look like to shrink ourselves down to the size of an ant’s foot, and travel inside the human body to witness these processes in action. Effectively communicating a complex disease pathophysiology, or the novel mechanism of action of a new drug, can be complex. This is especially difficult when the audience domain knowledge is limited or non-existent. Medical animation can help with this communication challenge in several ways.
Improved accessibility to visualisation
Visualisation is a core component of our ability to understand a concept. Ask 10 people to visualise an apple, and each will come up with a slightly different image, some apples smaller than others, some more round, some with bites taken. Acceptable, you say, we can move on to the next part of the story. Now ask 10 people to visualise how HIV’s capsid protein gets arranged into the hexamers and pentamers that form the viral capsid that holds HIV’s genetic material. This request may pose a challenge even to someone with some virology knowledge, and it is that inability to effectively visualise what is going on that holds us back from fully understanding the rest of the story. So how does medical animation help us to overcome this visualisation challenge?

Hal Barron, GSK's president of R&D and CSO, speaks to Endpoints News founder and editor John Carroll in London at Endpoints' #UKBIO19 summit on October 8, 2019

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron talks about a new era at GSK

Last week I had a chance to sit down with Hal Barron at Endpoints’ #UKBIO19 summit to discuss his views on R&D at GSK, a topic that has been central to his life since he took the top research post close to 2 years ago. During the conversation, Barron talked about changing the culture at GSK, a move that involves several new approaches — one of which involves celebrating their setbacks as they shift resources to the most promising programs in the pipeline. Barron also discussed his new alliances in the Bay Area — including his collaboration pact with Lyell, which we covered here — frankly assesses the pluses and minuses of the UK drug development scene, and talks about his plans for making GSK a much more effective drug developer.

This is one discussion you won’t want to miss. Insider and Enterprise subscribers can log-in to watch the video.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Flu Virus (Source: CDC)

FDA ex­pands Xofluza ap­proval as Roche strug­gles to catch loom­ing flu mar­ket

As a potentially powerful flu season looms, so does a big test for Roche and its new flu drug, Xofluza. The Swiss giant just got a small boost in advance of that test as the FDA expanded Xofluza’s indication to include patients at high risk of developing flu-related complications.

Xofluza (baloxavir marboxil) was approved last October in the US, the first landmark flu drug approval in 20 years and a much-needed green light for a company that had watched its leading flu drug Tamiflu get eaten alive by generics. Like its predecessor, the pill offered a reduction in flu symptoms but not a cure.

EMA backs sev­en ther­a­pies, in­clud­ing Mer­ck­'s Ebo­la vac­cine

The first-ever Ebola vaccine is on the precipice of approval after the European Medicine’s Agency (EMA) backed the Merck product in this week’s roster of recommendations.

The drugmaker $MRK began developing the vaccine, christened Ervebo, during the West African outbreak that occurred between 2014 and 2016, killing more than 11,000.

The current outbreak in the Democratic Republic of Congo (DRC) has shown case fatality rates of approximately 67%, the agency estimated. Earlier this year, the WHO declared the outbreak — which so far has infected more than 3,000 people — a public health emergency of international concern.